Greggs profits plunge: Britain’s weight-loss jab obsession chokes pastry and cake sales

01/18/2026

Reading time: about 2 minutes

Greggs profits hammered by Britain's fat jab obsession as habits shift from pastries and cakes

Greggs says a surge in appetite-suppressing weight-loss injections is changing what customers buy. Shoppers are choosing smaller portions and different ingredients, and the bakery chain is rethinking its menu to keep sales steady.

Why GLP-1 medications are altering eating habits

Doctors and pharmacists have seen a rise in prescriptions for GLP-1 drugs like Ozempic and Wegovy. These medications reduce appetite. As a result, people eat less and skip calorie-dense snacks.

The effect is behavioral as much as medical. Customers report smaller appetites and new preferences. That shift translates into fewer sales of large pastries and richer bakery items.

Greggs adjusts menu and product development

Greggs’ leadership says the firm is changing how it designs products. New items aim to match slimmer appetites and different nutritional goals.

  • Smaller portion sizes replace some larger classics.
  • Recipes with higher protein and lower fat are being explored.
  • Snack-format offerings get more attention than heavy pasties.

Executives stress that the company must keep its signature products while offering alternatives that reflect new demand. Balancing heritage items with healthier options is now a commercial priority.

How supermarkets are responding to the trend

Major grocers report similar patterns. Retailers note stronger sales in fresh and high-protein categories.

Tesco and sector reactions

Tesco’s executive team points to a shift toward fresh produce and protein-rich choices. The supermarket says it is expanding ranges to meet changing needs.

Industry analysts link slight dips in grocery volumes over certain periods to altered eating patterns. Some view those dips as early signs of a structural change.

Analysts’ take: short-term blip or lasting change?

Market watchers are split on the scale of the impact. Some see a temporary spike as more people try GLP-1 drugs.

  • Others warn of longer-term implications for volume-based sales.
  • Retail margins could shift if bulky, high-fat items lose popularity.
  • Brands reliant on indulgent products may need to innovate fast.

Reduced calorie consumption could reshape category performance across the food sector.

Additional pressures: prices and advertising rules

Smaller pack sizes and steady prices have been used by manufacturers to handle rising input costs. This trend can mimic the effects of appetite changes.

At the same time, new UK rules limit junk-food ads before 9pm. The policy aims to curb obesity and steer public behaviour.

Both economic pressure and tighter advertising create a compound force. Food firms must navigate cost rises, regulatory shifts, and evolving consumer tastes.

What retailers are doing now

  • Expanding low-calorie and protein-led ranges in stores.
  • Trialling smaller portion sizes in bakeries and cafés.
  • Investing in product development to meet new nutritional demands.
  • Monitoring sales data more closely to react to fast-moving trends.

Several chains say they will keep core products for loyal customers, while also rolling out trial items targeted at those using appetite-suppressing drugs.

Consumer choices and market signals to watch

Shoppers deciding between convenience and nutrition will shape the next retail cycle. Pay attention to:

  1. Sales growth in fresh produce and protein snacks.
  2. Product reformulations toward lower fat or smaller sizes.
  3. Promotions and merchandising aimed at health-conscious buyers.
  4. Regulatory changes that affect advertising and labelling.

Those signals will help predict whether the trend is transient or a durable shift.

Similar Posts:

Rate this post
See also  Labour car grant prompts iconic British automaker to slash prices

Leave a Comment

Share to...